Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jens Kaalby Thomsen"'
Autor:
Johan F. Paulsson, Jens Kaalby Thomsen, Annika Lindgren Sjölander, Christian Poulsen, Birgitte Schjellerup Wulff, Per-Olof Wahlund, Kilian Conde-Frieboes, Søren Østergaard, Marie Østergaard Pedersen
Publikováno v:
Pharmaceutical Research. 38:1369-1385
The anorectic effect of PYY3–36 makes it a potential pharmacological weight loss treatment. Modifications of the endogenous peptide to obtain commercially attractive pharmacological and biophysical stability properties are examined. Half-life exten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f411fe986b05fc92f7569a83399866d
https://doi.org/10.1007/s11095-021-03077-x
https://doi.org/10.1007/s11095-021-03077-x
Autor:
Christian, Poulsen, Marie Østergaard, Pedersen, Per-Olof, Wahlund, Annika, Sjölander, Jens Kaalby, Thomsen, Kilian W, Conde-Frieboes, Johan F, Paulsson, Birgitte S, Wulff, Søren, Østergaard
Publikováno v:
Pharmaceutical research. 38(8)
The anorectic effect of PYYHalf-life extended PYYDeamidation of asparagine in position 18 and 29 was observed upon incubation at 37°C. Asparagine in position 18 - but not position 29 - could be substituted to glutamine without detrimental effects on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44eba2d1563d226835592aabd480e098
https://pubmed.ncbi.nlm.nih.gov/34272643
https://pubmed.ncbi.nlm.nih.gov/34272643
Autor:
Jens Christian Norrild, Jens Kaalby Thomsen, Kristian Strømgaard, Johan F. Paulsson, Louise Albertsen, Julie J. Andersen
Peptide YY (PYY) is a gut hormone that activates the G protein-coupled neuropeptide Y (NPY) receptors, and because of its appetite reducing actions, it is evaluated as an antiobesity drug candidate. The C-terminal tail of PYY is crucial for activatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c5a4b1ae73d93f7f05b6894b2811d3
https://europepmc.org/articles/PMC4027376/
https://europepmc.org/articles/PMC4027376/
Autor:
Ib Jonassen, Mathias Norrman, Jens Kaalby Thomsen, Holger M. Strauss, Gerd Schluckebier, Svend Havelund, Anders V. Friderichsen, Dorte Bjerre Steensgaard
Publikováno v:
Biochemistry. 52(2)
Insulin degludec, an engineered acylated insulin, was recently reported to form a soluble depot after subcutaneous injection with a subsequent slow release of insulin and an ultralong glucose-lowering effect in excess of 40 h in humans. We describe t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b496c8903e0f17406ceb31b97680772
https://pubmed.ncbi.nlm.nih.gov/23256685
https://pubmed.ncbi.nlm.nih.gov/23256685